Yazar "Caliyurt, O" seçeneğine göre listele
Listeleniyor 1 - 8 / 8
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Aortic aneurysm and electroconvulsive therapy in elderly depressive patient(Lippincott Williams & Wilkins, 2003) Caliyurt, O; Tuglu, C; Vardar, EWe report the case of a 67-year-old single man with aortic aneurysm whose depression was successfully treated with electroconvulsive therapy. Metoprolol succinate was used for blood pressure control, and there were no cardiovascular side effects and no significant increase in blood pressure detected.Öğe Comparison of regional cerebral blood flow in early and late onset alcoholic patients(Springer, 2004) Vardar, E; Durmus-Altun, G; Erdogan, E; Firat, MF; Tuglu, C; Caliyurt, O; Abay, E[Abstract Not Available]Öğe Cotard's syndrome with schizophreniform disorder can be successfully treated with electroconvulsive therapy: case report(Cma-Canadian Medical Assoc, 2004) Caliyurt, O; Vardar, E; Tuglu, CWe report a case of Cotard's syndrome associated with psychotic symptoms. A 27-year-old man was admitted to hospital with the diagnosis of schizophreniform disorder. His presenting symptoms, which had started 1 month before hospital admission, were somatic delusions of gastrointestinal and cardiovascular malfunction and the absence of a stomach, which resulted in a decrease in weight from 75 kg to 63 kg in 1 month. Cranial computed tomographic images showed dilatation of the lateral and third ventricles, whereas magnetic resonance imaging revealed central atrophy and lateral ventricle dilatation. Single-photon emission computed tomography demonstrated left temporal, left frontal and left parietal hypoperfusion. The patient did not respond to antipsychotic therapies, but he was successfully treated with electroconvulsive therapy. This report emphasizes that Cotard's syndrome may be accompanied by lesions of the left hemisphere and that electroconvulsive therapy could be the first-line therapy in such patients with psychotic disorder.Öğe Effects of sertraline and venlafaxine on serum TNF-? in major depressive disorder(Elsevier Science Bv, 2003) Tuglu, C; Kara, H; Caliyurt, O; Vardar, E; Abay, E[Abstract Not Available]Öğe Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder(Springer, 2003) Tuglu, C; Kara, SH; Caliyurt, O; Vardar, E; Abay, ERationale. Over the last 15 years, an increasing body of evidence has suggested a causal relationship between depression and the immunological activation and hypersecretion of pro-inflammatory cytokines, such as interleukin-1, interleukin-6 and tumor necrosis factor-alpha (TNF-alpha). However, little is known about the probable relationship of serum TNF-alpha with major depressive disorder (MDD). Objective. To assess whether serum TNF-alpha levels could be associated with the clinical course of MDD. Subjects and methods. TNF-alpha and C-reactive protein (CRP) serum concentrations, erythrocyte sedimentation rate, and leukocyte count were measured in 26 MDD patients and in 17 controls. The measurements were repeated following 6 weeks of antidepressant treatment with selective serotonin re-uptake inhibitors. Psychopathological improvement and the severity of depression were evaluated with the Hamilton Depression Rating Scale (HAMD) and Beck Depression Inventory (BDI). Results. On admission, serum TNF-alpha and leukocyte count were significantly higher in MDD patients compared to controls (P<0.001 and P=0.005, respectively). With the antidepressant treatment, both HAMD and BDI scores decreased significantly (P<0.001 for both). Comparison of pre- and post-treatment measurements revealed that TNF-alpha, CRP, and leukocyte count decreased to levels comparable with those of the control subjects (P<0.001, P=0.01, and P=0.01, respectively). Conclusions. The results emphasized that some immunological parameters, such as CRP, leukocyte count and TNF-alpha, are significantly involved in the clinical course and treatment response in MDD. TNF-alpha in particular could be considered as a potential state marker in MDD.Öğe Partial sleep deprivation therapy combined with sertraline affects subjective sleep quality in major depressive disorder(Elsevier, 2005) Caliyurt, O; Guducu, FBackground and purpose: Earlier studies have shown an association between mood disorders and sleep regulation. Total or partial sleep deprivation was demonstrated to have rapid antidepressive effects in depression. Depressive symptoms recur after one night of recovery sleep, but relapse is less when patients are receiving medication. In this study, we examined the subjective sleep quality changes with the antidepressive therapy using partial sleep deprivation plus sertraline and sertraline monotherapy in patients with major depressive disorder. Patients and methods: Thirteen patients received six partial sleep deprivation therapies in addition to sertraline; the sleep schedule on deprivation nights started at 11:00 p.m. and ended at 3:00 a.m. Eleven patients were treated with sertraline monotherapy as a control group. Six nights of partial sleep deprivation were completed in the first two weeks. Subjective sleep quality was evaluated with the Pittsburgh Sleep Quality Index (PSQ1); depression and the accompanying anxiety were also assessed at baseline and at the end of the fourth week. Results: The late partial sleep deprivation (LPSD) group showed less increase in estimated sleep duration and less significant improvement in subjective sleep quality than the control group. Although decreased sleep latency and increased sleep efficiency are associated with the sleep deprivation, contrary results were found in our study. Conclusions: In conclusion, changes in subjective sleep quality could occur relative to the combined partial sleep deprivation therapy and to pharmacotherapy and must be differentiated from the rapid effects of sleep deprivation therapy and objective polysomnographic measures. (c) 2005 Elsevier B.V. All rights reserved.Öğe Partial sleep deprivation therapy combined with sertraline induces more rapid improvements in quality of life items in major depressive disorder(Elsevier Science Bv, 2005) Caliyurt, O; Guducu, FBackground: Total or partial sleep deprivation was showed to have rapid antidepressive effects in depression. Sleep deprivation therapy in major depression constitutes insufficient antidepressive treatment response and depressive symptoms reoccur after one night of recovery. Combination of antidepressant medication with sleep deprivation therapy is generally indicated. These combination therapies were found more favorable overall therapeutic effect than antidepressive monotherapy. Methods: In this study, we examined the Quality of Life changes with the antidepressive therapy using partial sleep deprivation plus sertraline and sertraline monotherapy in patients with major depressive disorder. Thirteen patients received six partial sleep deprivation therapies in addition to sertraline, that sleep schedule in deprivation nights started at 11:00-12:00 p.m. to 03:00 a.m. and 11 patients treated with sertraline monotherapy as a control group. Quality of Life was evaluated with the WHOQOL-100, depression and the accompanying anxiety were also assessed at baseline and at the end of the 4th week. Results: Patients treated with combination therapy improved significantly and more rapidly. Rapid improvement in quality of life in major depressive disorder was showed in patients treated with combination of late partial sleep deprivation and sertraline. Limitations: Small sample size, the lack of placebo group and short duration of the study are the main limitations. Conclusions: In clinical practice, QOL improvement can be accelerated using combination of partial sleep deprivation with the sertraline therapy. (c) 2005 Elsevier B.V. All rights reserved.Öğe Sleep quality and psychopathological features in obese binge eaters(Wiley, 2004) Vardar, E; Caliyurt, O; Arikan, E; Tuglu, CThe objectives of this study were to determine the prevalence of Binge Eating Disorder (BED) and to investigate the subjective sleep qualities and the psychopathological features of BED in treatment-seeking obese patients. Thirty-six treatment-seeking obese subjects and 37 control subjects were interviewed with the DSM-IV research criteria for BED, The Pittsburgh Sleep Quality Index (PSQI), Bulimic Investigatory Test, Edinburg (BITE) and SCL-90-R scales. Eight out of 36 treatment-seeking obese patients (22.2 per cent) met the criteria for BED. The PSQI global scores, sleep latencies and SCL-PSDI, SCL-interpersonal sensitivity subscale results were all significantly higher in treatment-seeking BED obese subjects than non-BED (N-BED) subjects and controls. Our findings suggest that BED appears to be a common disorder in treatment-seeking obese patients. The treatment-seeking obese BED patients suffer from more psychopathological problems than N-BED obese patients and controls, and the subjective sleep qualities are likely to be disrupted in patients with BED. Copyright (C) 2004 John Wiley Sons, Ltd.
